Pharma faces changes in drug development approvals
For the week of June 30:
Pharma executives that changes in the regulatory environment are changing the drug development process, based on the slow rate of approvals versus warnings, rejections, and delays.
The Wall Street Journal story that Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, does not believe the FDA is “‘more conservative’ about drug safety. Rather, she says, the industry’s faltering research efforts are mostly to blame for the fewer product approvals.”
Also:
Obesity is expected to be a $2 trillion market in four years, with more and more pharmaceutical companies developing diet treatments and medical devices for related surgeries.
A biochemist who started a social networking site in Seattle says that biotechs and pharma are still a year or two away from fully embracing Web 2.0.
Teen anti-smoking campaigns stall, with one CDC official blaming cuts at the state level for anti-smoking campaigns and continued promotion and advertising from cigarette companies.
